NCT06350773View on ClinicalTrials.gov

Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Group 2 Pulmonary Hypertension
Interventions
DRUG

tadalafil 20 mg then 40 mg if tolerated

Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.

Trial Locations (1)

62511

RECRUITING

Beni Suef University, Cairo

All Listed Sponsors
lead

Beni-Suef University

OTHER